FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
ACTH(4-10) analog neuropeptide
Overview
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, developed in Russia as a non-hormonal neuroactive peptide. It pairs the neuroactive ACTH(4-7) core (Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro that slows enzymatic degradation, giving a markedly longer in-vivo window than the native fragment while stripping the corticotropic activity of full-length ACTH. It is studied for nootropic, neuroprotective, and BDNF-modulating effects in cognitive and cerebrovascular research models. Every Vialdyne lot of Semax acetate is released at ≥99.0% HPLC main-peak purity, with a batch COA bundling RP-HPLC peak integration, peptide-content assay, water (Karl Fischer), acetic-acid counter-ion, residual solvents, and endotoxin. LC-MS/MS sequence confirmation and the raw chromatogram are available as documented add-ons on the same lot for labs qualifying a new reference source.
Applications & buyer fit
Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For in vivo workflows, endotoxin and microbial-limit testing on the specific lot is recommended at the COA stage.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for Semax, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
Research-use-only reference material. Semax is registered as a medicine in the Russian Federation but is not approved by the FDA or EMA; not for human or veterinary use. Buyers are responsible for verifying regulatory status in the destination market.
Frequently asked questions
Semax keeps the neuroactive ACTH(4-7) core (Met-Glu-His-Phe) but adds a C-terminal Pro-Gly-Pro tripeptide. The native ACTH(4-10) fragment is degraded within minutes and full-length ACTH drives cortisol release; the Pro-Gly-Pro extension slows enzymatic breakdown and removes the corticotropic (cortisol-raising) activity, leaving a peptide studied for cognitive and neuroprotective research without the endocrine effects of the parent hormone.
Each released lot carries a batch-specific COA: appearance, identification, HPLC purity (released ≥99.0% main-peak), peptide-content assay, related substances, water by Karl Fischer, acetic-acid counter-ion, residual solvents to ICH Q3C, bacterial endotoxin (LAL), heavy metals, and sterility. LC-MS/MS sequence confirmation and the raw chromatogram are available on request for method-development and reference-standard files.
Related peptides
